Literature DB >> 1965107

Inhibition of human herpesvirus 6 replication by 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (2HM-HBG) and other antiviral compounds.

A Akesson-Johansson1, J Harmenberg, B Wahren, A Linde.   

Abstract

The in vitro susceptibilities of human herpesvirus 6 to foscarnet; the guanosine analogs acyclovir, ganciclovir, and two isomers of 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine; and the thymidine analogs 3'-azido-3'-deoxythymidine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil were investigated. All compounds except 3'-azido-3'-deoxythymidine and 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil inhibited human herpesvirus 6 replication. The highest in vitro selectivity was obtained for 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1965107      PMCID： PMC172072          DOI： 10.1128/AAC.34.12.2417

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Susceptibility of human herpesvirus 6 to acyclovir.

Authors:  H Kikuta; H Lu; S Matsumoto
Journal:  Lancet       Date:  1989-10-07       Impact factor: 79.321

2.  Susceptibility of human herpesvirus 6 to acyclovir and ganciclovir.

Authors:  S K Russler; M A Tapper; D R Carrigan
Journal:  Lancet       Date:  1989-08-12       Impact factor: 79.321

3.  Human herpesvirus-6 (HHV-6, HBLV) in sarcoidosis and lymphoproliferative disorders.

Authors:  P Biberfeld; A L Petrén; A Eklund; C Lindemalm; T Barkhem; M Ekman; D Ablashi; Z Salahuddin
Journal:  J Virol Methods       Date:  1988-09       Impact factor: 2.014

4.  Human herpesvirus 6 is closely related to human cytomegalovirus.

Authors:  G L Lawrence; M Chee; M A Craxton; U A Gompels; R W Honess; B G Barrell
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

5.  The replication of viral and cellular DNA in human herpesvirus 6-infected cells.

Authors:  D Di Luca; G Katsafanas; E C Schirmer; N Balachandran; N Frenkel
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

6.  Brief report: primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor.

Authors:  K N Ward; J J Gray; S Efstathiou
Journal:  J Med Virol       Date:  1989-06       Impact factor: 2.327

Review 7.  Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Authors:  B Oberg
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

8.  In vitro sensitivity of human herpesvirus-6 to antiviral drugs.

Authors:  H Agut; H Collandre; J T Aubin; D Guétard; V Favier; D Ingrand; L Montagnier; J M Huraux
Journal:  Res Virol       Date:  1989 May-Jun

9.  In vitro inhibition of human herpesvirus-6 by phosphonoformate.

Authors:  H Z Streicher; C L Hung; D V Ablashi; K Hellman; C Saxinger; J Fullen; S Z Salahuddin
Journal:  J Virol Methods       Date:  1988-09       Impact factor: 2.014

10.  Human herpes virus-6 increases HIV-1 expression in co-infected T cells via nuclear factors binding to the HIV-1 enhancer.

Authors:  B Ensoli; P Lusso; F Schachter; S F Josephs; J Rappaport; F Negro; R C Gallo; F Wong-Staal
Journal:  EMBO J       Date:  1989-10       Impact factor: 11.598
View more
  12 in total

1.  Selection and characterization of varicella-zoster virus variants resistant to (R)-9-[4-hydroxy-2-(hydroxymethy)butyl]guanine.

Authors:  T I Ng; Y Shi; H J Huffaker; W Kati; Y Liu; C M Chen; Z Lin; C Maring; W E Kohlbrenner; A Molla
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 2.  Human herpesvirus 6.

Authors:  D K Braun; G Dominguez; P E Pellett
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

3.  Real-time PCR as a versatile tool for investigating the susceptibility of human herpesvirus 6 to antiviral agents.

Authors:  Muriel Macé; Chaysavanh Manichanh; Pascale Bonnafous; Stéphanie Précigout; David Boutolleau; Agnès Gautheret-Dejean; Henri Agut
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 4.  Human herpesvirus-6 infections.

Authors:  C A Jones; D Isaacs
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

Review 5.  Current and potential treatments for ubiquitous but neglected herpesvirus infections.

Authors:  Jonathan E Gable; Timothy M Acker; Charles S Craik
Journal:  Chem Rev       Date:  2014-10-02       Impact factor: 60.622

Review 6.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

Review 7.  Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.

Authors:  M Ogata; T Fukuda; T Teshima
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

8.  The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.

Authors:  J Neyts; G Andrei; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 9.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Effect of (r)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine (H2G) and AZT-lipid-PFA on human herpesvirus-6B infected cells.

Authors:  Karen Yao; Christel Hoest; Farzin Rashti; Timm C Schott; Steven Jacobson
Journal:  J Clin Virol       Date:  2009-06-12       Impact factor: 3.168
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.